Last reviewed · How we verify
Diltiazem treated group
Diltiazem blocks L-type calcium channels in cardiac and vascular smooth muscle, reducing calcium influx and decreasing heart rate and blood pressure.
Diltiazem blocks L-type calcium channels in cardiac and vascular smooth muscle, reducing calcium influx and decreasing heart rate and blood pressure. Used for Hypertension, Angina pectoris, Atrial fibrillation with rapid ventricular response.
At a glance
| Generic name | Diltiazem treated group |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Non-dihydropyridine calcium channel blocker |
| Target | L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Diltiazem is a non-dihydropyridine calcium channel blocker that inhibits the inward movement of calcium ions through L-type calcium channels in the sinoatrial and atrioventricular nodes, as well as in vascular smooth muscle. This results in decreased automaticity and conduction velocity in the heart, reduced myocardial contractility, and vasodilation of coronary and peripheral arteries. These effects collectively reduce heart rate, lower blood pressure, and improve myocardial oxygen supply-demand balance.
Approved indications
- Hypertension
- Angina pectoris
- Atrial fibrillation with rapid ventricular response
Common side effects
- Headache
- Dizziness
- Constipation
- Edema
- Bradycardia
- Asthenia/fatigue
Key clinical trials
- Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 (PHASE1)
- Comparative Evaluation of MEBO Ointment and Topical Diltiazem Ointment in the Treatment of Acute Anal Fissure (PHASE2)
- Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation (PHASE4)
- The Efficacy of Botulinum Toxin Alone Versus Combined Botulinum Toxin and Topical Diltiazem in Chronic Anal Fissure
- Pre-diltiazem, Calcium Versus Placebo for Atrial Fibrillation With Rapid Ventricular Response (PHASE2)
- The Efficacy of Asacol (Mesalazine) Suppository on the Treatment of Diarrhea-Induced Acute Fissure (PHASE1, PHASE2)
- Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) (PHASE4)
- Efficacy of Oral Verapamil and Oral Diltiazim on Reduction of Intraoperative Bleeding During Endoscopic Sinus Surgery Under General Anesthesia (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diltiazem treated group CI brief — competitive landscape report
- Diltiazem treated group updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI